Nautilus Biotechnology (NASDAQ:NAUT) Stock Price Up 6.3% – What’s Next?

Nautilus Biotechnology, Inc. (NASDAQ:NAUT) shares rose 6.3% on Wednesday . The company traded as high as $2.20 and last traded at $2.18. Approximately 200,542 shares changed hands during mid-day trading, an increase of 9% from the average daily volume of 183,975 shares. The stock had previously closed at $2.05.

Wall Street Analysts Forecast Growth

Several analysts recently commented on NAUT shares. Weiss Ratings restated a “sell (d-)” rating on shares of Nautilus Biotechnology in a report on Wednesday, October 8th. Wall Street Zen upgraded shares of Nautilus Biotechnology from a “sell” rating to a “hold” rating in a research report on Tuesday, November 18th. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock presently has an average rating of “Sell” and an average target price of $2.50.

Nautilus Biotechnology Stock Performance

The company has a market cap of $275.36 million, a price-to-earnings ratio of -4.36 and a beta of 1.49. The company’s 50 day moving average price is $2.02 and its 200 day moving average price is $1.29.

Nautilus Biotechnology (NASDAQ:NAUT) last released its quarterly earnings data on Monday, October 27th. The company reported ($0.11) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.15) by $0.04. On average, equities research analysts forecast that Nautilus Biotechnology, Inc. will post -0.57 EPS for the current fiscal year.

Institutional Trading of Nautilus Biotechnology

Several large investors have recently made changes to their positions in the stock. Jacobs Levy Equity Management Inc. raised its stake in shares of Nautilus Biotechnology by 18.1% in the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 301,012 shares of the company’s stock valued at $254,000 after acquiring an additional 46,153 shares in the last quarter. Squarepoint Ops LLC boosted its position in Nautilus Biotechnology by 29.5% during the third quarter. Squarepoint Ops LLC now owns 131,827 shares of the company’s stock worth $111,000 after purchasing an additional 30,005 shares during the period. GSA Capital Partners LLP grew its holdings in Nautilus Biotechnology by 46.5% during the third quarter. GSA Capital Partners LLP now owns 259,203 shares of the company’s stock valued at $219,000 after purchasing an additional 82,295 shares during the last quarter. Ashton Thomas Private Wealth LLC bought a new position in shares of Nautilus Biotechnology in the third quarter valued at approximately $38,000. Finally, Clarius Group LLC raised its position in shares of Nautilus Biotechnology by 14.1% in the third quarter. Clarius Group LLC now owns 1,209,646 shares of the company’s stock valued at $1,022,000 after purchasing an additional 149,186 shares during the period. Institutional investors own 50.71% of the company’s stock.

Nautilus Biotechnology Company Profile

Nautilus Biotechnology is a life sciences company developing a next-generation proteomics platform that aims to provide high-resolution, single-molecule protein analysis. Its core technology combines proprietary microfluidics, advanced optics and custom reagents to capture and identify thousands of proteins simultaneously, offering researchers detailed insights into cellular processes and disease biology. The company’s platform is designed to improve sensitivity, reproducibility and throughput compared with traditional mass spectrometry approaches.

Founded in 2016 and headquartered in Seattle, Washington, Nautilus Biotechnology serves pharmaceutical and biotechnology companies, academic institutions and research organizations seeking to accelerate drug discovery and biomarker research.